⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for nonmyeloablative allogeneic hematopoietic stem cell transplantation

Every month we try and update this database with for nonmyeloablative allogeneic hematopoietic stem cell transplantation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi AnemiaNCT00453388
Acute Myeloid L...
de Novo Myelody...
Fanconi Anemia
Previously Trea...
Allogeneic Bone...
Cyclophosphamid...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Nonmyeloablativ...
Total-Body Irra...
- Fred Hutchinson Cancer Center
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid LeukemiaNCT00003145
Accelerated Pha...
Childhood Chron...
Chronic Myeloge...
Chronic Phase o...
Recurrent Disea...
Fludarabine Pho...
Total-Body Irra...
Nonmyeloablativ...
Peripheral Bloo...
Cyclosporine
Mycophenolate M...
Therapeutic All...
Laboratory Biom...
- 74 YearsFred Hutchinson Cancer Center
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerNCT00027820
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Myelo...
Childhood Renal...
Chronic Myelomo...
Clear Cell Rena...
de Novo Myelody...
Metastatic Rena...
Previously Trea...
Progression of ...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Refractory Chil...
Refractory Chro...
Renal Medullary...
Type 1 Papillar...
Type 2 Papillar...
Untreated Adult...
Untreated Adult...
Untreated Child...
Fludarabine Pho...
Total-Body Irra...
Peripheral Bloo...
Nonmyeloablativ...
Cyclosporine
Mycophenolate M...
- Fred Hutchinson Cancer Center
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesNCT00454480
Leukemia
Myelodysplastic...
alemtuzumab
arsenic trioxid...
azacitidine
busulfan
clofarabine
cytarabine
daunorubicin hy...
fludarabine pho...
gemtuzumab ozog...
melphalan
tipifarnib
DNA methylation...
cytogenetic ana...
gene expression...
mutation analys...
diagnostic labo...
immunologic tec...
allogeneic hema...
nonmyeloablativ...
- National Cancer Institute (NCI)
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in RemissionNCT00045435
Acute Myeloid L...
Adult Acute Meg...
Adult Acute Min...
Adult Acute Mon...
Adult Acute Mon...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Erythrole...
Adult Pure Eryt...
Secondary Acute...
nonmyeloablativ...
fludarabine pho...
total-body irra...
cyclosporine
mycophenolate m...
peripheral bloo...
55 Years - Fred Hutchinson Cancer Center
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney CancerNCT00005851
Recurrent Renal...
Stage IV Renal ...
fludarabine pho...
total-body irra...
nonmyeloablativ...
cyclosporine
mycophenolate m...
peripheral bloo...
therapeutic all...
laboratory biom...
- 74 YearsFred Hutchinson Cancer Center
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersNCT00397813
Atypical Chroni...
Chronic Myelomo...
de Novo Myelody...
Essential Throm...
Myeloproliferat...
Paroxysmal Noct...
Polycythemia Ve...
Polycythemia Ve...
Primary Myelofi...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Refractory Cyto...
Refractory Cyto...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Total-Body Irra...
50 Years - 75 YearsFred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaNCT00005803
Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersNCT00397813
Atypical Chroni...
Chronic Myelomo...
de Novo Myelody...
Essential Throm...
Myeloproliferat...
Paroxysmal Noct...
Polycythemia Ve...
Polycythemia Ve...
Primary Myelofi...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Refractory Cyto...
Refractory Cyto...
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Total-Body Irra...
50 Years - 75 YearsFred Hutchinson Cancer Center
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00995059
Multiple Myelom...
Refractory Mult...
nonmyeloablativ...
allogeneic bone...
bortezomib
melphalan
anti-thymocyte ...
sirolimus
tacrolimus
total-body irra...
18 Years - Mayo Clinic
Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure SyndromeNCT00731328
Leukemia
Myelodysplastic...
Nonmalignant Ne...
Paroxysmal Noct...
nonmyeloablativ...
- 75 YearsAsan Medical Center
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney CancerNCT00005851
Recurrent Renal...
Stage IV Renal ...
fludarabine pho...
total-body irra...
nonmyeloablativ...
cyclosporine
mycophenolate m...
peripheral bloo...
therapeutic all...
laboratory biom...
- 74 YearsFred Hutchinson Cancer Center
Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to TreatmentNCT00802568
Multiple Myelom...
anti-thymocyte ...
busulfan
fludarabine pho...
allogeneic bone...
nonmyeloablativ...
18 Years - 65 YearsNational Cancer Institute (NCI)
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaNCT00005803
Prolymphocytic ...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Recurrent Chron...
Recurrent Non-H...
Recurrent Small...
Refractory Chil...
Refractory Chro...
Refractory Hodg...
Refractory Non-...
Refractory Smal...
T-Cell Chronic ...
T-Cell Prolymph...
Autologous Hema...
Autologous-Allo...
Carmustine
Cyclophosphamid...
Cyclosporine
Cytarabine
Etoposide
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic Aut...
Total-Body Irra...
- 75 YearsFred Hutchinson Cancer Center
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaNCT01954784
Refractory Mult...
Stage I Multipl...
Stage II Multip...
Stage III Multi...
fludarabine pho...
total-body irra...
nonmyeloablativ...
cyclosporine
mycophenolate m...
bortezomib
lenalidomide
laboratory biom...
18 Years - Case Comprehensive Cancer Center
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic LeukemiaNCT00425802
Leukemia
Lymphoma
anti-thymocyte ...
filgrastim
graft-versus-tu...
rituximab
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
nonmyeloablativ...
total-body irra...
18 Years - 70 YearsMemorial Sloan Kettering Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or NilotinibNCT00036738
Adult Acute Lym...
Adult B Acute L...
Blastic Phase
Childhood Acute...
Childhood B Acu...
Chronic Myeloge...
Chronic Phase o...
Recurrent Adult...
Recurrent Child...
Recurrent Disea...
Cyclosporine
Dasatinib
Fludarabine Pho...
Imatinib Mesyla...
Mycophenolate M...
Nilotinib
Nonmyeloablativ...
Peripheral Bloo...
Therapeutic All...
Total-Body Irra...
- 70 YearsFred Hutchinson Cancer Center
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaNCT00793572
Refractory Plas...
Autologous Hema...
Bortezomib
Cyclosporine
Cyclosporine
Fludarabine Pho...
Laboratory Biom...
Melphalan
Mycophenolate M...
Nonmyeloablativ...
Peripheral Bloo...
Syngeneic Bone ...
Total-Body Irra...
18 Years - Fred Hutchinson Cancer Center
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological CancerNCT00816413
Chronic Myelopr...
Leukemia
Lymphoma
Myelodysplastic...
Nonmalignant Ne...
cyclosporine
mycophenolate m...
pentostatin
cytogenetic ana...
fluorescence in...
protein analysi...
flow cytometry
immunoenzyme te...
laboratory biom...
reduced-intensi...
nonmyeloablativ...
peripheral bloo...
total-body irra...
19 Years - 75 YearsUniversity of Nebraska
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic CancerNCT00296023
Chronic Myelopr...
Leukemia
Lymphoma
Multiple Myelom...
Myelodysplastic...
anti-thymocyte ...
filgrastim
therapeutic all...
busulfan
fludarabine pho...
methotrexate
tacrolimus
nonmyeloablativ...
peripheral bloo...
18 Years - 75 YearsUniversity of California, San Francisco
Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple MyelomaNCT00054353
Refractory Mult...
fludarabine pho...
melphalan
total-body irra...
mycophenolate m...
cyclosporine
nonmyeloablativ...
peripheral bloo...
laboratory biom...
18 Years - 70 YearsFred Hutchinson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: